| Citation: |
CAI Jiayu, LI Yong, ZHANG Danna, HU Weiqun. Adverse effects of 0.01% atropine eye drops in treatment of children with myopia[J]. Journal of Clinical Medicine in Practice, 2022, 26(17): 138-141. DOI: 10.7619/jcmp.20221373
|
To observe the adverse reactions of 0.01% atropine eye drops in treatment of children with myopia.
The children in observation group wore full correction single focus frame glasses, and every night before going to bed, children had to put one drop of 0.01% atropine eye drops into the conjunctival sac; children in control group only wore full correction single focus frame glasses. Before administration and after 6 months of treatment, the best corrected near vision, diopter, intraocular pressure, ocular axis, pupil diameter, adjustment range, tear film rupture time and tear secretion test were examined in both groups.
There were no significant differences in refractive diopter and optic axis between two groups before treatment(P > 0.05). After 6 months of treatment, refractive diopter was -1.38 (-2.19, -0.50) D in the observation group and -2.25 (-2.94, -1.75) D in the control group (P < 0.05); after 6 months of treatment, the length of optic axis in the observation group was (24.17±0.72) mm, and (24.67±0.88) mm in the control group, and the difference was statistically significant (P < 0.05). After 6 months of treatment, the pupils of the observation group were slightly enlarged, the amplitude of adjustment was decreased, the tear film rupture time was shortened, and the tear secretion test value was decreased, and the differences were statistically significant (P < 0.05). No blurred vision for near objects, dry, red and itching eyes occurred in children of both groups.
0.01% atropine eye drops can effectively slow down the growth of the ocular axis and the progression of myopia degree in children with myopia, and the adverse reactions are relatively mild, which have no significant impacts on children′s daily life and learning.
| [1] |
中华医学会眼科学分会眼视光学组. 儿童屈光矫正专家共识(2017)[J]. 中华眼视光学与视觉科学杂志, 2017, 19(12): 705-710. doi: 10.3760/cma.j.issn.1674-845X.2017.12.001
|
| [2] |
瞿佳, 吕帆, 徐良德. 切实做好儿童青少年近视眼防控工作[J]. 中华眼科杂志, 2019, 55(2): 81-85. doi: 10.3760/cma.j.issn.0412-4081.2019.02.001
|
| [3] |
姜珺. 近视管理白皮书(2019)[J]. 中华眼视光学与视觉科学杂志, 2019, 21(3): 161-165.
|
| [4] |
SUFFEE BIBI SHAMINAH, SHIPKOLYE MOHAMMAD ASHIFF, 吕帆. 阿托品控制儿童近视的meta分析[J]. 中华实验眼科杂志, 2019, 37(7): 559-565. doi: 10.3760/cma.j.issn.2095-0160.2019.07.012
|
| [5] |
贺美男, 魏瑞华. 阿托品控制近视增长的研究进展[J]. 中华眼视光学与视觉科学杂志, 2016, 18(10): 632-635. doi: 10.3760/cma.j.issn.1674-845X.2016.10.013
|
| [6] |
孙芸芸, 李仕明, 康梦田, 等. 低浓度阿托品控制近视眼进展适宜浓度与剂型的临床研究[J]. 中华眼科医学杂志: 电子版, 2019, 9(4): 212-217. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYB201904005.htm
|
| [7] |
CHIA A, CHUA W H, CHEUNG Y B, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)[J]. Ophthalmology, 2012, 119(2): 347-354. doi: 10.1016/j.ophtha.2011.07.031
|
| [8] |
CHIA A, LU Q S, TAN D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops[J]. Ophthalmology, 2016, 123(2): 391-399. doi: 10.1016/j.ophtha.2015.07.004
|
| [9] |
符爱存, 赵兵新, 张俊杰, 等. 近视儿童应用0.01%硫酸阿托品滴眼液的不良反应[J]. 中华实验眼科杂志, 2018, 36(6): 449-453.
|
| [10] |
符爱存, 荣军博, 王卫群, 等. 0.01%与0.02%阿托品滴眼液对青少年近视控制效果的随机对照研究[J]. 中华实验眼科杂志, 2022, 40(3): 253-259.
|
| [11] |
陈玳西, 何鲜桂, 许迅. 阿托品防控近视眼的安全性研究进展[J]. 中华眼科杂志, 2021, 57(4): 299-304.
|
| [12] |
荣军博, 符爱存, 吕勇, 等. 0.01%阿托品滴眼液控制学龄儿童近视发展的疗效[J]. 中华实验眼科杂志, 2020, 38(6): 494-498. https://www.cnki.com.cn/Article/CJFDTOTAL-BFYX202101028.htm
|
| [13] |
LARKIN G L, TAHIR A, EPLEY K D, et al. Atropine 0.01% eye drops for myopia control in American children: a multiethnic sample across three US sites[J]. Ophthalmol Ther, 2019, 8(4): 589-598. doi: 10.1007/s40123-019-00217-w
|
| [14] |
SACCHI M, SERAFINO M, VILLANI E, et al. Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients[J]. Acta Ophthalmol, 2019, 97(8): e1136-e1140.
|
| [15] |
宫博腾, 魏瑞华. 阿托品控制近视相关机制研究进展[J]. 中华实验眼科杂志, 2018, 36(12): 951-955.
|
| [16] |
李双莲, 殷小龙. 阿托品滴眼液眼部不良反应的研究进展[J]. 南昌大学学报: 医学版, 2020, 60(4): 99-102. https://www.cnki.com.cn/Article/CJFDTOTAL-JXYB202004022.htm
|
| [17] |
林小俊, 陈琴, 段文华, 等. 间断使用1%阿托品滴眼液控制儿童近视进展的临床研究[J]. 中国学校卫生, 2021, 42(2): 177-180. https://www.cnki.com.cn/Article/CJFDTOTAL-XIWS202102006.htm
|
| [18] |
刘真, 王甲, 李广林. 0.01%阿托品对青少年近视调节参数的影响[J]. 中华眼视光学与视觉科学杂志, 2019, 21(12): 942-946. doi: 10.3760/cma.j.issn.1674-845X.2019.12.011
|
| [19] |
钟梅, 吕勇, 符爱存, 等. 质量分数0.01%和0.02%阿托品滴眼液对近视儿童瞳孔直径和调节幅度影响的一年随机、双盲、临床对照试验[J]. 中华实验眼科杂志, 2019, 37(7): 540-545.
|
| [20] |
张艳玲, 查屹, 邢丽娟, 等. 0.01%低浓度阿托品滴眼液对近视儿童调节功能和视疲劳的影响研究[J]. 中国斜视与小儿眼科杂志, 2021, 29(3): 7-10. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXS202103003.htm
|
| [21] |
邰雪, 申颖, 赵海霞, 等. 儿童干眼症的病因及治疗进展[J]. 中华眼科医学杂志: 电子版, 2019, 9(4): 252-256. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYB201904011.htm
|
| [22] |
刘祖国, 李炜. 关注儿童干眼的临床诊断和治疗[J]. 中华眼科杂志, 2018, 54(6): 406-408.
|
| [23] |
曾艳, 杨晓英, 李娇. 普拉洛芬联合玻璃酸钠对干眼症青少年患者视功能、泪液炎性因子及视觉相关生存质量的影响[J]. 实用临床医药杂志, 2021, 25(20): 33-36. doi: 10.7619/jcmp.20211415
|
| [24] |
范浩博, 唐秀平, 邹云春, 等. 0.01%阿托品对亚洲青少年儿童中低度近视屈光度与眼轴影响的Meta分析[J]. 国际眼科杂志, 2021, 21(5): 854-860. https://www.cnki.com.cn/Article/CJFDTOTAL-GJYK202105026.htm
|
| [25] |
查桂平, 汪卓琼. 0.01%阿托品联合中药离子导入控制儿童中低度近视进展的临床观察[J]. 中国现代医生, 2020, 58(9): 97-100. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS202009025.htm
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: